Use of erythropoietin
AssigneeEpoplus GmbH & Co. KG
InventorsFerdinand Hermann Bahlmann, Hermann Haller
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
Claims16
A method for therapeutic treatment of diabetes mellitus, said method comprising administering a pharmaceutical composition comprising a subpolycythemic erythropoietin dose corresponding to a weekly dose of 1 to 90 international units (IU) EPO/kg body weight to a subject in need of said therapeutic treatment for healing said diabetes mellitus.
Dependencies are inferred from the claim text.